AUAnezi Uzendu

Anezi Uzendu

*This is an algorithmically generated author record based on publicly available information.

Anezi Uzendu has a total of 93 co-authors. Here are the top co-authors by number of shared publications:

  • John A. Spertus

    University of Missouri-Kansas City's Healthcare Institute for Innovations in Quality, Kansas City, Missouri, USA; Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA

    3 shared publications
  • Nobuhiro Ikemura

    Department of Cardiology, Keio University School of Medicine, Tokyo, Japan

    3 shared publications
  • Amit P. Amin

    Dartmouth-Hitchcock Medical Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA

    2 shared publications
  • Cornelia Anderson

    Department of Science and Quality, American College of Cardiology, Washington, DC, USA

    2 shared publications
  • Dan Nguyen

    University of Missouri Kansas City’s Healthcare Institute for Innovations in Quality and Saint Luke’s Mid America Heart Institute

    2 shared publications
  • Glenn Chertow

    Department of Medicine, Stanford University, Stanford, California, USA

    2 shared publications

Latest Publications

  • Open Access

    Association of Acute Kidney Injury Risk and Same‐Day Discharge Practices After Percutaneous Coronary Intervention

    by Anezi Uzendu, Rayan El Zein, Jennifer A. Rymer, Dan D. Nguyen, R. Angel Garcia, Nobuhiro Ikemura, Neel Butala, Howard M. Julien, Saket Girotra, Dharam J. Kumbhani, et al.

    Background: Same‐day discharge (SDD) after percutaneous coronary intervention (PCI) may be altered when complications occur. We sought to determine whether risk of the most common complication, acute kidney injury (AKI), is associated with SDD in practice. Methods: Using the NCDR (National Cardiovascular Data Registry) CathPCI registry, we calculated the AKI risk for elective PCIs from 2018 to 2022 using the NCDR prediction model. Hierarchical logistic regression models were constructed to predict SDD with AKI risk and procedural variables as fixed effects, and site as a random effect. Trends in SDD rate across AKI risk categories were described and variability across sites was quantified using median odds ratios (ORs). Results: Among 1 033 096 eligible patients, 414 297 (40.1%) had SDD after PCI and rates increased throughout the study period (27.9% in 2018 to 53.4% in 2022; 1.9% per quarter). Higher AKI risks were associated with lower SDD rates (OR, 0.97 per 1% increase in AKI risk [95% CI 0.968–0.971]) although even in 2022, 41.2% of high‐risk patients underwent SDD. Marked variation in SDD practices was observed across sites (overall median OR, 3.75 [95% CI 2.63–5.34]) even among the highest risk group (median OR, 3.60 [95% CI 2.34–5.56]). Conclusions: Although patients at higher risk of AKI are less likely to undergo SDD overall, currently, 2 in 5 patients with >10% AKI risk are discharged the day of their procedure with marked variation across sites. Further work is needed to better understand the postdischarge risk of SDD in patients at higher AKI risk to improve delivery and safety of PCI.


  • Open Access

    Diversifying the Interventional Cardiology Workforce: Why It Matters and How to Achieve It

    by Anezi Uzendu, Triston B.B.J. Smith, Jason Galo, Deepali Tukaye, Yolanda Hendley, Zarina Sharalaya, Shrilla Banerjee, Jason F. Deen, Ki Park, Melvin Echols, et al.


  • Trends and Physician-Level Variation in Contrast Volume During Percutaneous Coronary Intervention

    by Nobuhiro Ikemura, Paul S. Chan, David J. Cohen, Kevin F. Kennedy, Anezi Uzendu, Shun Kohsaka, John A. Spertus


  • Sudden Cardiac Arrest in Athletes

    by Marius Chukwurah, Jeomi Okwara, Anezi Uzendu

  • Open Access

    Outcomes After Noncardiac Surgery Performed Within 2 Years of Percutaneous Coronary Intervention

    by Neel M. Butala, Annika Hebbe, Binita Shah, Nathaniel R. Smilowitz, Bilal Aijaz, Anezi Uzendu, Peter Boulos, Stephen W. Waldo

    Background: Limited data exist on noncardiac surgery patients with prior percutaneous coronary intervention (PCI) in the contemporary era. The objective was to examine rate, characteristics, and outcomes of patients who underwent noncardiac surgery within 2 years of PCI and develop a risk model of factors that predict long‐term postoperative outcomes among patients with recent PCI. Methods and Results: Patients in the Veterans Affairs Surgical Quality Improvement Program database who underwent noncardiac surgery between October 1, 2017 and September 30, 2021 were included. Patients with versus without PCI within 2 years were propensity matched to examine major adverse cardiovascular events (MACE), defined as a 1‐year composite of mortality, revascularization, and rehospitalization for myocardial infarction or stroke. Among patients with recent PCI, multivariable logistic regression was used to develop a risk model to predict 1‐year postoperative MACE. Among 334 828 patients undergoing surgery, 2297 (0.68%) had PCI within 2 years. Among 9160 propensity‐matched veterans, there was no difference in MACE between patients with and without preceding PCI (hazard ratio [HR], 1.04 [95% CI, 0.96–1.17]). Patients with versus without preceding PCI within 2 years had lower risk of all‐cause death (HR, 0.83 [95% CI, 0.72–0.96]) but higher risk of revascularization (HR, 1.88 [95% CI, 1.50–2.36]) at 1 year. A 13‐component MACE prediction model among patients with recent PCI had moderate discrimination (area under the receiver operating characteristic curve 0.73 derivation, 0.72 validation). Conclusions: Among patients who underwent surgery, risk of MACE did not differ, but the risk of revascularization was higher and all‐cause death was lower in patients with versus without recent PCI. A risk model can be used to stratify risk of surgery among patients with preceding PCI.


  • Developing an Individualized Patient Decision Aid for Chronic Coronary Disease Based on the ISCHEMIA Trial: A Mixed-Methods Study

    by Dan D. Nguyen, Carole Decker, Christina M. Pacheco, Stacy L. Farr, Christine Fuss, Ruth M. Masterson Creber, Stephanie Pena, Nobuhiro Ikemura, Anezi I. Uzendu, David J. Maron, et al.

    BACKGROUND: Pursuing initial invasive or conservative management of chronic coronary disease (CCD) is a preference-sensitive decision that should include shared decision-making. Communicating the benefits of either approach is challenging, as individual patients rarely achieve the population-averaged outcomes reported in clinical trials. Our objective was to develop a patient decision aid (PDA) with patient-specific estimates of outcomes for initial invasive versus conservative management of CCD, based on the ISCHEMIA trial (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches). METHODS: This was a multiphase mixed-methods study using focus groups of outpatients with CCD, caregivers, clinicians, and researchers. Focus groups were held in Kansas City, MO and New York City, NY between September 2021 and June 2022. Patients with CCD were included if they had a positive stress test within 1 year. Phase 1 focused on patient priorities for outcomes to guide treatment decisions. Phase 2 involved PDA development and refinement. Phase 3 involved further refinement and member checking. Key themes involving shared decision-making and treatment preferences were elicited from focus groups using a deductive approach to develop a PDA representing the outcomes most important to patients. RESULTS: Of 46 patient and caregiver participants, the mean age was 63.5 years, 53% were female, 61% were White, 24% were Black, and 9% were Hispanic. When deciding between treatments, participants valued shared decision-making but generally deferred decisions to clinicians. The outcomes most important to participants were survival and quality of life, followed by physical functioning and symptoms. To represent these outcomes, participants favored simple visualizations, such as a speedometer or health meter. When deciding between treatment options, participants preferred to use the PDA collaboratively with a clinician instead of as a stand-alone tool. CONCLUSIONS: Our novel, patient-centered approach to developing a PDA for CCD with patient-specific outcomes has the potential to rapidly translate clinical trial results to individual patients and support shared decision-making.


  • Case Volumes and Outcomes Among Early-Career Interventional Cardiologists in the United States

    by Jennifer A. Rymer, Dennis I. Narcisse, Angel Chen, Daniel Wojdyla, Sarah Ashley, Abdulla A. Damluji, Binita Shah, Michael G. Nanna, Rajesh Swaminathan, J. Antonio Gutierrez, et al.


  • Open Access

    A Cross-Sectional Survey of Fixed-Dose Combination Antihypertensive Medicine Prescribing in Twenty-Four Countries, Including Qualitative Insights

    by Edel O’hAgan, Daniel McIntyre, Tu Nguyen, Kit Mun Tan, Peter Hanlon, Maha Siddiqui, Dzudie Anastase, Toon Wei Lim, Anezi Uzendu, Tan Van Nguyen, et al.

    Background: Treatment inertia, non-adherence and non-persistence to medical treatment contribute to poor blood pressure (BP) control worldwide. Fixed dose combination (FDC) antihypertensive medicines simplify prescribing patterns and improve adherence. The aim of this study was to identify factors associated with prescribing FDC antihypertensive medicines and to understand if these factors differ among doctors worldwide. Methods: A cross-sectional survey was conducted online from June 2023 to January 2024 to recruit doctors. We collaborated with an international network of researchers and clinicians identified through institutional connections. A passive snowballing recruitment strategy was employed, where network members forwarded the survey link to their clinical colleagues. The survey instrument, developed through a literature review, interviews with academic and clinical researchers, and pilot testing, assessed participants perspectives on prescribing FDC antihypertensive medicines for hypertension. Participants rated their level of agreement (5-point Likert scale) with statements representing six barriers and four facilitators to FDC use. Findings: Data from 191 surveys were available for analysis. 25% (n = 47) of participants worked in high-income countries, 38% (n = 73) in upper-middle income, 25% (n = 48) in lower-middle income, 6% (n = 10) in low-income countries. Forty percent (n = 70) of participants were between 36–45 years of age; two thirds were male. Cost was reported as a barrier to prescribing FDC antihypertensive medicines [51% (n = 87) agreeing or strongly agreeing], followed by doctors’ confidence in BP measured in clinic [40%, (n = 70)], access [37%, (n = 67)], appointment duration [35%, (n = 61)], concerns about side-effects [(21%, n = 37)], and non-adherence [12%, (n = 21)]. Facilitators to FDC antihypertensive polypills prescribing were clinician facing, such as access to educational supports [79%, (n = 143)], more BP measurement data [67%, (n = 120)], a clinical nudge in health records [61%, (n = 109)] and patient-facing including improved patient health literacy [49%, (n = 88)]. The levels of agreement and strong agreement across all barriers and facilitators were similar for participants working in higher or lower income countries. Across all countries, participants rated FDC antihypertensive medications highly valuable for managing patients with non-adherence, (82% reported high or very high value), for patients with high pill burden (80%). Interpretation: Cost and access were the most common barriers to prescribing FDCs across high- and low-income countries. While greater educational support for clinicians was perceived as the leading potential facilitator of FDC use, this seems unlikely to be effective without addressing access.


  • Contemporary Methods for Predicting Acute Kidney Injury After Coronary Intervention

    by Anezi Uzendu, Kevin Kennedy, Glenn Chertow, Amit P. Amin, Jay S. Giri, Jennifer A. Rymer, Sripal Bangalore, Kimberly Lavin, Cornelia Anderson, Tracy Y. Wang, et al.